Skip to content

Vitamin D and Endometrial Receptivity in Infertile Women

Effect of Vitamin D on Vaginal / Endometrial Biomarkers and Endometrial Receptivity in Women With Fertility Problems

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04721899
Enrollment
105
Registered
2021-01-25
Start date
2021-01-15
Completion date
2026-08-01
Last updated
2024-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

vitamin D, endometrial receptivity, infertility, recurrent pregnancy loss, recurrent implantation failure

Brief summary

This is a prospective study comparing vaginal and endometrial biomarkers and the trophoblast spheroid attachment rate in women with fertility problems before and after taking Vitamin D for 8 weeks.

Detailed description

The aim of this study is to assess the effect of vitamin D supplementation on vaginal / endometrial biomarkers and endometrial receptivity in women with fertility problems. Women will have vaginal swab and endometrial biopsy twice. The first endometrial biopsy is performed using a Pipelle sampler 7 days after luteinizing hormone surge (LH+7) at baseline and the attachment rate of the trophoblast spheroid onto the isolated endometrial epithelial cells will be assessed to assess endometrial receptivity at baseline. Implantation biomarkers will be checked. They will take Vitamin D 50,000 IU once per week for 4 weeks, followed by 50,000 IU once every 2 weeks for 4 weeks. After 8 weeks of Vitamin D, a second vaginal swab and endometrial biopsy using a Pipelle sampler by standard technique will be collected from the patients 7 days after luteinizing hormone surge (LH+7) and the endometrial receptivity will be compared. The laboratory staff will not know whether the patient is taking any vitamin D when performing the trophoblast spheroid attachment assay/ biomarkers.

Interventions

DIETARY_SUPPLEMENTVitamin D

Vitamin D 50,000 IU once per week for 4 weeks, followed by 50,000 IU once every 2 weeks for 4 weeks

Sponsors

The University of Hong Kong
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Age of women \< 40years old * Normal uterine cavity as demonstrated by pelvic scanning with or without saline infusion sonogram or hysteroscopy * Regular ovulatory cycles They will be divided into three groups: * RIF patients (n=35)- those who have failed to get pregnant after replacing four or more cleavage stage embryos or two or more blastocysts in two consecutive transfers. * RPL patients (n=35)- those who have failed in three pregnancies before 24 weeks of gestation and includes embryonic and fetal losses. * 'Infertile group'(n=35)- infertility except RIF and RPL, e.g. those seeking for preimplantation genetic testing, male factor infertility, unexplained infertility.

Exclusion criteria

* History of any medical condition or medications that may predispose to vitamin D sensitivity, altered vitamin D metabolism and/ or hypercalcemia, including active tuberculosis or current therapy for tuberculosis, sarcoidosis, history of renal/ ureteral stones, parathyroid disease, renal or liver failure or current use of anti-convulsants * Taking vitamin D supplement * Endometrial polyp or fibroid distorting the uterine cavity * Presence of hydrosalpinx not corrected surgically * Refusal to join the study • Discontinuation criteria- * If the woman becomes pregnant during the study * Pelvic inflammatory disease/ uterine perforation after endometrial biopsy * Vitamin D toxicity (hypercalcemia) * Withdrawal by patient

Design outcomes

Primary

MeasureTime frameDescription
Change in endometrial receptivity8 weeksAssessed by the attachment rate of trophoblast spheroid attachment assay onto the isolated endometrial epithelial cells

Countries

Hong Kong

Contacts

Primary ContactJennifer KY Ko
jenko@hku.hk22554647

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026